Abstract
Background and Objectives
The aim of this study was to evaluate type II radical hysterectomy with or without adjuvant therapy as a treatment for patients with pelvic lymph node metastasis (PLNM) and stage IB–IIB cervical carcinoma.
Methods
A total of 288 patients with stage IB–IIB cervical carcinoma and confirmed PLNM who underwent a type II radical hysterectomy between 1995 and 2005 were retrospectively evaluated.
Results
The 5‐year overall survival (OS) rate for this cohort was 65.6%, and independent prognostic factors identified for PLNM patients included a non‐squamous cell histological subtype and parametrial involvement. Survival differences between patients that received or did not receive adjuvant treatment were also evaluated, and the 5‐year OS and DFS rates for patients who did not receive adjuvant therapy (47 and 41.4%, respectively) were much lower than the rates for patients who did receive adjuvant therapies (67.7 and 59.4%, respectively). However, these differences were not statistically significant (OS, P= 0.057; DFS, P= 0.080).
Conclusions
Type II radical hysterectomy, in combination with adjuvant therapies, is an efficient treatment for PLNM patients with stage IB–IIB cervical cancer. J. Surg. Oncol. 2011; 104:480–485. © 2011 Wiley‐Liss, Inc.